Is Helix BioPharma Corp. (HBP.TO) a Buy, Sell, or Hold?
TSX : HBP.TO
Helix BioPharma Corp.
$1.4 CAD
-$0.03 (-2.1%)
- Volume
- 2.34K
- Average Volume
- 1.4K
- Market Capitalization
- $106.93M
- P/E Ratio
- -31.82
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $5.40
- Year Low
- $0.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.45
Company Overview
TSX
Thomas Mehrling
Biotechnology
Healthcare
HBP.TO
7
CA
CAD
Liquidity Metrics
0.02
0.45
0.45
0.42
0.00
Sales & Valuation
-$
0.00
7.28
-33.34
-0.04
Profitability
-$0.0934
-$5.2M
0.00%
0.00%
-21.54%
-15.54%
P/E Metrics
-31.82
-0.12
-0.12
Analyst Price Target & Rating
1/5
0 Analysts
%
Financial Health Scores
-5.39
2/9
-$3.7M
$21.38M
$6.69M
-$3.09M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Thomas Mehrling | CEO & Chief Medical Officer |
| Natalia L. Butterworth | Corporate Secretary |
| Veronika Kandziora | Chief Operating Officer |
| Helen Middleton | General Counsel |
| Rohit Babbar | Chief Financial Officer |
| Jacek Antas | Chairman & Corporate Secretary |
| Davide Guggi | Chief Technology Officer |
| Jessica Kourniaktis DPHIL | Director of Communications |
Poll Results
No votes yet today — be the first to share your view!
About Helix BioPharma Corp. (TSX:HBP.TO) Stock
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council C ... anada.
Frequently Asked Questions
-
What is the current Helix BioPharma Corp. (HBP.TO) stock price?
-
Helix BioPharma Corp.(TSX:HBP.TO) stock price is $1.4 in the last trading session. During the trading session, HBP.TO stock reached the peak price of $5.4 while $0.95 was the lowest point it dropped to. The percentage change in HBP.TO stock occurred in the recent session was --2.1% while the dollar amount for the price change in HBP.TO stock was -$0.03.
-
HBP.TO's industry and sector of operation?
-
The TSX listed HBP.TO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HBP.TO?
-
Thomas Mehrling | CEO & Chief Medical Officer
Natalia L. Butterworth | Corporate Secretary
Veronika Kandziora | Chief Operating Officer
Helen Middleton | General Counsel
Rohit Babbar | Chief Financial Officer -
How many employees does HBP.TO have?
-
Number of HBP.TO employees currently stands at 7. HBP.TO operates from 9120 Leslie Street, Richmond Hill, ON L4B 3J9, CA.
-
Link for HBP.TO official website?
-
Official Website of HBP.TO is: https://www.helixbiopharma.com
-
How do I contact HBP.TO?
-
HBP.TO could be contacted at phone #905 841 2300 and can also be accessed through its website. HBP.TO operates from 9120 Leslie Street, Richmond Hill, ON L4B 3J9, CA.
-
How many shares of HBP.TO are traded daily?
-
The average number of HBP.TO shares traded daily for last 3 months was 1.4K.
-
What is the market cap of HBP.TO currently?
-
The market value of HBP.TO currently stands at $106.93M with its latest stock price at $1.4